| Income Statement | 2025-07-31 | |||
|---|---|---|---|---|
| Research and development expenses | 21,270,678 | |||
| General and administrative expenses | 5,934,125 | |||
| Total operating expenses | 27,204,803 | |||
| Operating loss | -27,204,803 | |||
| Financial income (expenses), net | 114,511 | |||
| Change in fair value of the warrant liability | -758,364 | |||
| Share of loss on equity investment | -224,212 | |||
| Net loss for the year | -26,556,140 | |||
| Net loss attributable to non-controlling interest | -244,273 | |||
| Net loss for the year attributable to briacell | -26,311,867 | |||
| Net loss per share attributable to briacell - basic | -62.19 | |||
| Net loss per share attributable to briacell - diluted | -62.19 | |||
| Weighted average number of shares () used in computing net loss per share attributable to ordinary shareholders, basic | 423,114 | |||
| Weighted average number of shares () used in computing net loss per share attributable to ordinary shareholders, diluted | 423,114 | |||
BriaCell Therapeutics Corp. (BCTXZ)
BriaCell Therapeutics Corp. (BCTXZ)